Virginia Cannabis FBI Investigation — Federal Probe Into State Dispensaries

Executive Summary

Federal investigators executed search warrants at both a Virginia state legislator's office and a licensed cannabis dispensary on May 30, 2026, marking a significant escalation in federal scrutiny of state-legal marijuana operations. The FBI's coordinated searches targeted locations connected to Virginia's regulated cannabis market, which launched retail sales in January 2024 under the Cannabis Control Authority. The investigation represents a rare federal intervention into a state-licensed program operating under Virginia Code § 4.1-1500 et seq., raising immediate questions about the interplay between state legalization frameworks and federal enforcement priorities under the Controlled Substances Act.

The searches occurred approximately 28 months after Virginia opened its first adult-use dispensaries, a market that generated $127 million in sales during its first full year of operation according to the Cannabis Control Authority. While the specific focus of the FBI investigation remains undisclosed, the dual targeting of both a legislative office and a retail operation suggests potential concerns beyond routine compliance matters. Federal authorities have not filed charges or issued public statements detailing the investigation's scope as of May 30, 2026.

This development arrives during a period of heightened tension between state cannabis programs and federal enforcement agencies, particularly following the Department of Justice's January 2026 guidance memo emphasizing prosecutorial discretion in states with "robust regulatory frameworks." Virginia's program, which requires vertical integration and caps the number of licenses at 450 statewide, has been cited as a model for regulatory oversight. The FBI's involvement introduces uncertainty for the state's 73 currently operating dispensaries and the estimated 12,000 patients and consumers who rely on legal access.

Why This Matters

The Virginia cannabis FBI investigation carries implications for state-legal marijuana programs nationwide, affecting operators, investors, patients, and the broader federalism debate over drug policy. Virginia's market serves a population of 8.6 million residents across a state that legalized adult-use possession in July 2021 and retail sales in January 2024, making it the first Southern state to establish a fully operational recreational cannabis market.

For the state's licensed operators, federal scrutiny threatens business continuity and access to capital. Virginia's 73 active dispensaries collectively employ approximately 2,400 workers and represent over $340 million in private investment since licensing began in 2022, according to industry filings with the Cannabis Control Authority. A federal investigation targeting any component of the supply chain creates immediate compliance concerns for multi-state operators with Virginia licenses, including Curaleaf, Green Thumb Industries, and Trulieve, all of which maintain operations in the state.

Medical patients face particular vulnerability. Virginia's medical program, which predates adult-use legalization and serves 48,000 registered patients as of April 2026, provides legal access to individuals with qualifying conditions including cancer, PTSD, and epilepsy. Federal enforcement actions that disrupt supply chains or force dispensary closures directly impact patient access to physician-recommended treatments, creating a healthcare access crisis for vulnerable populations.

The investigation also tests the durability of state-federal cannabis détente. The Cole Memorandum, rescinded in 2018 but informally observed by many U.S. Attorneys, established an eight-factor framework prioritizing federal resources away from state-compliant operators. The Biden administration's October 2022 pardon of federal simple possession offenses and the ongoing DEA rescheduling process under 21 U.S.C. § 811 suggested a trajectory toward reduced federal interference. An FBI investigation in Virginia—a state with Democratic governance and a regulatory structure designed to prevent diversion—signals potential policy reversal or identifies specific compliance failures serious enough to warrant federal intervention despite broader reform momentum.

Financially, the investigation introduces risk premiums across the cannabis sector. Virginia operators already face effective tax rates exceeding 70% due to Internal Revenue Code § 280E, which disallows business expense deductions for Schedule I controlled substances. Federal criminal exposure compounds these challenges, potentially triggering cross-default provisions in debt agreements and forcing operators to increase cash reserves against legal defense costs. The ripple effects extend to ancillary businesses—security firms, testing laboratories, packaging suppliers—that depend on dispensary operations for revenue.

Background and History

Virginia's path to cannabis legalization began with incremental medical reforms before accelerating to full adult-use legalization in a compressed 18-month timeline between 2020 and 2021. Understanding the FBI investigation requires tracing the regulatory framework's development and the political compromises that shaped the state's unique market structure.

Medical Cannabis Foundation (2015-2020)

Virginia's medical cannabis program originated with House Bill 1445 in 2015, which authorized cannabidiol (CBD) oil and THC-A oil for treatment-resistant epilepsy patients. The law, codified at Virginia Code § 54.1-3408.3, permitted possession but created no legal supply mechanism, forcing patients to obtain products from out-of-state sources in violation of federal law. In 2017, the General Assembly expanded qualifying conditions to include any condition for which a physician issued a written certification, effectively creating a broad medical program without retail infrastructure.

The breakthrough came in 2020 with Senate Bill 976, which established five vertically integrated pharmaceutical processors authorized to cultivate, process, and dispense medical cannabis products. The Board of Pharmacy issued licenses to Columbia Care, Dharma Pharmaceuticals, gLeaf Medical, Green Leaf Medical, and Dalitso LLC between August and November 2020. The first medical dispensary opened in Manassas on March 12, 2021, with products testing at THC concentrations up to 25% for flower and 70% for concentrates.

Adult-Use Legalization (2021)

On April 7, 2021, Governor Ralph Northam signed House Bill 2312 and Senate Bill 1406, making Virginia the first Southern state to legalize adult-use cannabis. The legislation, effective July 1, 2021, permitted possession of up to one ounce of marijuana and home cultivation of up to four plants per household for individuals 21 and older. Critically, the bills delayed retail sales until January 1, 2024, creating a 30-month gap between legalization and regulated commerce.

This delay reflected political compromise. Republican legislators demanded time to establish a "social equity" licensing framework prioritizing applicants from communities disproportionately impacted by prohibition. The final legislation created the Cannabis Control Authority as an independent agency within the executive branch, replacing the Board of Pharmacy's oversight role. The CCA received authority to issue up to 450 retail licenses, 150 cultivation licenses, 60 manufacturing licenses, and 10 testing laboratory licenses under Virginia Code § 4.1-1502.

Regulatory Implementation (2021-2023)

The Cannabis Control Authority convened its first meeting on November 15, 2021, and spent 14 months developing comprehensive regulations. The CCA published emergency regulations on January 18, 2023, establishing a three-tier licensing system: cultivation facilities, manufacturing processors, and retail dispensaries. Unlike many states, Virginia prohibited horizontal integration—single entities could not hold licenses across all three tiers—but required vertical integration within tiers, meaning cultivators had to control their distribution networks.

The social equity framework allocated 30% of licenses to applicants meeting specific criteria: individuals with prior cannabis convictions, residents of historically over-policed census tracts identified by the Virginia Equity Index, or graduates of historically Black colleges and universities. The CCA received 1,847 applications during the initial window from March through May 2023, far exceeding the 450 available retail licenses. A lottery system conducted on August 3, 2023, selected provisional winners, who then underwent background checks and financial audits.

Market Launch and Early Operations (2024-2025)

Virginia's first adult-use dispensaries opened on January 2, 2024, in Richmond, Norfolk, and Alexandria. By the end of January 2024, 31 dispensaries had commenced operations statewide. The CCA reported first-month sales of $8.4 million, with an average transaction value of $73. The state imposed a 21% excise tax at the retail level plus standard 5.3% sales tax, generating $1.76 million in tax revenue during the inaugural month.

The market expanded rapidly through 2024. By December 2024, 68 dispensaries operated across 42 of Virginia's 95 counties and 18 independent cities. Total 2024 sales reached $127 million, below initial projections of $180 million but consistent with mature markets' first-year performance. The CCA attributed slower-than-expected growth to competition from Washington D.C.'s gifting market, which allows unlicensed sales within 15 miles of Virginia's northern border, and from North Carolina's unregulated hemp-derived THC products sold in gas stations and smoke shops.

Through 2025, the market stabilized with modest growth. Annual sales reached $156 million, representing 23% year-over-year growth. The CCA issued an additional 47 licenses during 2025's second application window, bringing the total licensed dispensaries to 115, though only 73 had opened physical locations by May 2026. Industry analysts attributed the gap to capital constraints—buildout costs for compliant dispensaries averaged $420,000, and many social equity licensees struggled to secure financing given federal prohibition's impact on banking access.

Federal Enforcement Context

Federal cannabis enforcement in state-legal markets has followed an inconsistent trajectory since Colorado and Washington launched adult-use sales in 2014. The Obama administration's Cole Memorandum, issued August 29, 2013, directed federal prosecutors to deprioritize enforcement against state-compliant operators absent aggravating factors like sales to minors, interstate diversion, or involvement of criminal enterprises. Attorney General Jeff Sessions rescinded the Cole Memorandum on January 4, 2018, but most U.S. Attorneys continued exercising prosecutorial discretion against state-legal operators.

The Trump administration brought sporadic enforcement actions, primarily targeting operators in California and Oklahoma accused of diversion to illegal markets. Notable cases included the March 2020 indictment of CannaCraft executives in Sonoma County, California, for allegedly diverting 20,000 pounds of cannabis to out-of-state buyers, and the September 2021 raids on 23 Oklahoma dispensaries accused of foreign ownership violations under state law.

The Biden administration signaled a more permissive stance. President Biden's October 6, 2022, proclamation pardoned all federal simple possession offenses and directed HHS and DOJ to review marijuana's Schedule I classification under the Controlled Substances Act. On August 30, 2023, HHS recommended rescheduling marijuana to Schedule III, acknowledging accepted medical use and lower abuse potential than Schedule I or II substances. The DEA published a Notice of Proposed Rulemaking on May 21, 2024, initiating the formal rescheduling process, which remains pending as of May 2026.

Despite this reform trajectory, federal enforcement has not ceased. The FBI and DEA conducted a joint operation in New York in November 2025, raiding 14 unlicensed dispensaries in Manhattan and Brooklyn and seizing $2.3 million in cash and 1,400 pounds of product. Those operations, however, targeted unlicensed operators—the Virginia investigation's focus on a state-licensed dispensary represents a departure from recent enforcement patterns.

Key Players

Federal Bureau of Investigation

The FBI's Richmond Field Office, which covers all of Virginia, executed the May 30, 2026, search warrants. The field office, located at 1970 East Parham Road in Richmond, employs approximately 340 special agents and focuses on public corruption, white-collar crime, and organized crime in addition to national security matters. FBI involvement, as opposed to DEA-led enforcement, suggests the investigation may involve allegations beyond Controlled Substances Act violations—potentially including financial crimes, public corruption, or violations of the Racketeer Influenced and Corrupt Organizations Act under 18 U.S.C. § 1961.

The FBI operates under DOJ guidelines that prioritize federal resources toward cases involving significant interstate activity, public safety threats, or corruption of government processes. The decision to execute search warrants at a legislator's office indicates the investigation likely meets one or more of these elevated thresholds. The FBI has not issued a public statement regarding the investigation's scope or targets as of May 30, 2026.

Virginia Cannabis Control Authority

The Cannabis Control Authority, established under Virginia Code § 4.1-1501, oversees all aspects of the state's marijuana market. The five-member board, appointed by the Governor and confirmed by the General Assembly, includes Chair Kimberly Mosley, a former Richmond prosecutor; Vice Chair Dr. Terrence Graves, a public health researcher at Virginia Commonwealth University; and members representing law enforcement, agriculture, and social equity advocacy. Executive Director Aaron Silva manages day-to-day operations with a staff of 87 regulators, investigators, and administrative personnel.

The CCA conducts routine compliance inspections of all licensed facilities, reviewing inventory tracking through the state's seed-to-sale system (operated by BioTrack THC), testing protocols, and security measures. The agency has authority to suspend or revoke licenses for violations of Virginia Code § 4.1-1500 et seq. or administrative regulations at 4 VAC 5-10 et seq. The CCA has issued 23 license suspensions and 4 revocations since the market opened in January 2024, primarily for inventory discrepancies and failure to maintain required security systems. The agency has not publicly commented on whether the FBI investigation relates to any prior compliance actions.

Unnamed Virginia Legislator

Public reporting identifies the legislator whose office was searched but does not specify their role in cannabis policy or any alleged connection to the dispensary operation. Virginia's General Assembly includes 140 members across the House of Delegates and Senate. During the 2024 legislative session, 17 delegates and 8 senators sponsored or co-sponsored cannabis-related legislation, including bills addressing social equity licensing, tax revenue allocation, and interstate commerce provisions. The legislator's identity and specific involvement remain undisclosed pending further investigation developments.

Targeted Dispensary

The dispensary subject to the FBI search operates under a license issued during Virginia's initial application window in 2023. While the specific business name has not been publicly confirmed, the facility reportedly holds both medical and adult-use licenses, permitting sales to registered patients and recreational consumers. Virginia's dual-license structure allows dispensaries to serve both markets from the same location, provided they maintain separate inventory tracking and comply with distinct labeling requirements under 4 VAC 5-10-140.

Licensed dispensaries in Virginia must maintain $2 million in liability insurance, implement 24-hour video surveillance retaining footage for 90 days, employ licensed pharmacists or pharmacy technicians as patient consultants, and submit to unannounced CCA inspections. Product testing requirements mandate analysis for potency, pesticides, heavy metals, microbial contaminants, and mycotoxins at independent laboratories accredited under ISO/IEC 17025 standards. All sales must be recorded in the BioTrack system within 24 hours, creating an auditable chain of custody from cultivation through retail transaction.

Legal and Regulatory Framework

The Virginia cannabis FBI investigation sits at the intersection of state legalization under Virginia Code § 4.1-1500 et seq. and federal prohibition under the Controlled Substances Act, 21 U.S.C. § 801 et seq. This legal framework creates inherent tensions that shape enforcement priorities and compliance obligations.

Federal Law: Controlled Substances Act

Under 21 U.S.C. § 812, marijuana remains a Schedule I controlled substance, defined as having high abuse potential, no accepted medical use, and lack of accepted safety for use under medical supervision. Schedule I classification makes cultivation, distribution, and possession federal felonies under 21 U.S.C. § 841, punishable by up to five years imprisonment for first-time offenders and up to life imprisonment for large-scale operations involving 1,000 kilograms or more.

The Controlled Substances Act contains no exception for state-legal operations. The Supremacy Clause of the U.S. Constitution, Article VI, Clause 2, establishes that federal law preempts conflicting state law. However, the anti-commandeering doctrine, articulated in Printz v. United States, 521 U.S. 898 (1997), prevents the federal government from compelling state enforcement of federal law. This creates a practical reality where states can decline to criminalize marijuana under state law, but cannot immunize conduct from federal prosecution.

The Rohrabacher-Farr Amendment, enacted annually since 2014 as part of federal appropriations bills, prohibits the Department of Justice from using federal funds to prevent states from "implementing their own laws that authorize the use, distribution, possession, or cultivation of medical marijuana." Courts have interpreted this provision narrowly in United States v. McIntosh, 833 F.3d 1163 (9th Cir. 2016), holding that it bars prosecution only of individuals in strict compliance with state medical marijuana laws. The amendment does not protect adult-use operations and expires annually unless renewed, creating ongoing uncertainty.

Virginia State Law: Cannabis Control Act

Virginia Code § 4.1-1500 et seq., the Cannabis Control Act, establishes a comprehensive regulatory framework governing all aspects of the marijuana supply chain. The law permits adults 21 and older to possess up to one ounce of marijuana, cultivate up to four plants per household, and purchase products from licensed dispensaries. The Act creates the Cannabis Control Authority with exclusive authority to license and regulate commercial cannabis operations.

Licensing requirements under Virginia Code § 4.1-1502 mandate criminal background checks, financial audits demonstrating $500,000 in liquid capital for dispensary applicants, and detailed operating plans addressing security, inventory control, employee training, and community impact. The law prohibits licensees from holding financial interests in more than five retail locations and requires at least 51% ownership by Virginia residents for all license types.

Virginia Code § 4.1-1603 establishes criminal penalties for unlicensed cultivation and distribution, maintaining felony charges for large-scale illegal operations while reducing simple possession violations to civil infractions with $25 fines. The law explicitly states that compliance with state licensing requirements does not provide immunity from federal prosecution, acknowledging the ongoing conflict with federal law.

Tax and Banking Implications

Internal Revenue Code § 280E prohibits businesses trafficking in Schedule I or II controlled substances from deducting ordinary business expenses when calculating federal tax liability. Cannabis operators can deduct only cost of goods sold, resulting in effective tax rates of 70% or higher on gross receipts. Virginia dispensaries face this federal tax burden despite state-legal status, creating significant financial pressure and incentivizing cash-basis operations to minimize documented revenue.

Banking access remains severely limited. The Bank Secrecy Act, 31 U.S.C. § 5311 et seq., requires financial institutions to file Suspicious Activity Reports (SARs) for transactions involving proceeds of illegal activity. Because marijuana remains federally illegal, banks serving cannabis clients must file SARs and risk prosecution for money laundering under 18 U.S.C. § 1956. The FinCEN guidance issued February 14, 2014, provides a framework for banks to serve state-legal operators while maintaining BSA compliance, but most national banks decline cannabis accounts due to regulatory risk. Virginia operators rely primarily on state-chartered credit unions and cannabis-focused financial services companies operating under the FinCEN framework.

Relevant Case Law

Federal courts have consistently upheld the federal government's authority to prosecute state-legal cannabis operations. In Gonzales v. Raich, 545 U.S. 1 (2005), the Supreme Court held that the Commerce Clause grants Congress authority to prohibit intrastate marijuana cultivation even when conducted in compliance with California's medical marijuana law. The Court reasoned that local cultivation affects interstate markets for marijuana and therefore falls within federal regulatory power.

In United States v. Oakland Cannabis Buyers' Cooperative, 532 U.S. 483 (2001), the Court rejected a medical necessity defense to federal marijuana charges, holding that the Controlled Substances Act's classification of marijuana as Schedule I precludes any medical use exception. These precedents establish that state legalization provides no defense to federal prosecution, though they do not compel federal enforcement against state-compliant operators.

Market and Business Implications

The FBI investigation introduces immediate operational and financial risks for Virginia's cannabis industry, with potential ripple effects across multi-state operators and ancillary service providers. The state's 73 active dispensaries generated $156 million in sales during 2025, supporting approximately 2,400 direct employees and an estimated 1,800 additional jobs in cultivation, manufacturing, testing, and support services.

Multi-State Operator Exposure

Several publicly traded multi-state operators maintain Virginia licenses, including Curaleaf Holdings (CSE: CURA), which operates four dispensaries in Virginia Beach, Richmond, Fairfax, and Roanoke. Green Thumb Industries (CSE: GTII) holds three Virginia licenses, and Trulieve Cannabis Corp. (CSE: TRUL) operates two locations. These companies face particular vulnerability because federal investigations in one state can trigger regulatory reviews in other jurisdictions and impact access to capital markets.

Curaleaf reported $1.38 billion in revenue across 156 dispensaries in 18 states during fiscal year 2025, with Virginia operations contributing an estimated $18 million or 1.3% of total revenue. A federal investigation affecting Virginia licenses could trigger material adverse event disclosures under securities regulations, potentially impacting the company's $2.1 billion market capitalization. The company's $350 million senior secured notes due 2027 include cross-default provisions that could accelerate repayment obligations if federal charges result in license revocations.

Capital Markets Impact

Cannabis operators access capital primarily through Canadian exchanges, private equity, and specialized debt funds, as U.S. exchanges prohibit listings of companies violating federal law. The investigation may increase risk premiums demanded by lenders and equity investors. Cannabis-focused debt typically carries interest rates of 12-18%, compared to 6-8% for comparable non-cannabis businesses. Federal enforcement actions in Virginia could push rates higher, particularly for operators with exposure to the state.

Institutional investors have increased cannabis allocations following HHS's August 2023 rescheduling recommendation, with cannabis-focused funds raising $1.8 billion in new capital during 2024 and 2025 combined. A high-profile federal investigation could slow this momentum, particularly if it reveals systemic compliance failures or corruption within a state-regulated market. Conversely, if the investigation targets isolated bad actors rather than structural program deficiencies, it may reassure investors that federal enforcement focuses on legitimate compliance concerns rather than blanket opposition to state legalization.

Wholesale Pricing Dynamics

Virginia's wholesale marijuana prices have declined steadily since market launch, following patterns observed in mature markets. Wholesale flower prices averaged $2,800 per pound in January 2024, falling to $1,650 per pound by April 2026, according to Cannabis Benchmarks data. This 41% decline reflects increased cultivation capacity outpacing retail expansion—Virginia licensed 89 cultivation facilities but only 73 dispensaries have opened, creating supply-demand imbalance.

Federal enforcement uncertainty may accelerate price declines if cultivators increase production to generate cash reserves against potential legal costs, or if dispensaries reduce inventory purchases due to operational uncertainty. Alternatively, if the investigation results in license suspensions or revocations, reduced supply could support prices. Historical data from California's 2020 enforcement actions against unlicensed operators showed temporary 8-12% wholesale price increases as supply contracted.

Ancillary Business Risks

Virginia's cannabis industry supports a network of ancillary businesses providing security, testing, packaging, legal, and accounting services. These companies generally face lower federal risk because they do not touch the plant, but they remain economically dependent on licensed operators. A significant enforcement action that closes dispensaries or halts cultivation would immediately impact ancillary revenue streams.

Cannabis testing laboratories, required to analyze all products before retail sale under 4 VAC 5-10-130, charge $200-400 per sample and process an estimated 35,000 samples annually across Virginia's market. Security companies providing required video surveillance and alarm systems generate approximately $8 million annually from Virginia cannabis clients. These businesses typically maintain diversified client bases, but cannabis often represents 15-30% of revenue for firms serving the industry.

What Experts Say

Legal analysts and industry observers emphasize that the FBI's involvement, rather than DEA-led enforcement, suggests the investigation may extend beyond Controlled Substances Act violations to encompass financial crimes or public corruption. The dual targeting of a legislative office and a dispensary indicates potential concerns about improper influence in the licensing process or regulatory oversight.

According to cannabis attorney Rachel Gillette, who represents operators in Colorado and has testified before Congress on federal-state cannabis conflicts, FBI investigations in state-legal markets typically involve allegations of bribery, money laundering, or organized crime connections rather than simple CSA violations. The FBI's public corruption units focus on cases where government officials allegedly received benefits in exchange for favorable regulatory treatment, she noted in a May 2025 presentation to the National Cannabis Industry Association.

The Marijuana Policy Project, a national advocacy organization that supported Virginia's legalization effort, emphasized in a May 30, 2026, statement that isolated investigations should not undermine confidence in state regulatory frameworks. The organization noted that Virginia's Cannabis Control Authority has demonstrated robust oversight through regular compliance inspections and enforcement actions against violators, suggesting the state's regulatory structure functions as intended.

Financial analysts at Viridian Capital Advisors, a cannabis-focused investment bank, observed in their May 2026 market report that federal investigations create short-term volatility but rarely result in systemic market disruption unless they reveal widespread compliance failures. The firm noted that previous high-profile investigations, including the 2019 probe of Massachusetts' Cannabis Control Commission, resulted in individual prosecutions but did not halt market operations or trigger broader federal crackdowns.

Dr. Beau Kilmer, co-director of the RAND Drug Policy Research Center, has published extensive research on state cannabis markets and federal enforcement patterns. In a February 2026 analysis, he noted that federal prosecutors increasingly focus on cases involving interstate diversion, unlicensed operations, or corruption rather than pursuing state-compliant operators. This enforcement evolution reflects resource constraints and political considerations, as public support for marijuana legalization reached 70% in November 2025 Gallup polling.

What's Next

The investigation's trajectory will depend on whether federal authorities file criminal charges, the scope of any alleged violations, and the response from Virginia state officials and the cannabis industry. Several key decision points will shape outcomes over the coming months.

The immediate next step involves the FBI's analysis of materials seized during the May 30, 2026, searches. Federal investigators typically spend 60-180 days reviewing documents, electronic records, and financial data before determining whether to present evidence to a grand jury. If the investigation involves public corruption allegations, prosecutors will likely seek cooperation from lower-level participants before charging decision-makers, a process that can extend timelines to 12-18 months.

The Cannabis Control Authority faces decisions about whether to suspend licenses pending the investigation's outcome. Virginia Code § 4.1-1509 authorizes the CCA to suspend licenses when "the public health, safety, or welfare imperatively requires emergency action." The agency must balance protecting the regulatory program's integrity against the risk of penalizing licensees before any charges are filed. The CCA's next scheduled board meeting occurs June 15, 2026, and may address the investigation.

Virginia's General Assembly could respond with legislative action when it reconvenes in January 2027. Potential measures include enhanced background check requirements for licensees, stricter financial disclosure rules, or provisions explicitly prohibiting legislators from holding financial interests in cannabis businesses. The legislature's response will likely depend on what the investigation reveals about potential gaps in existing oversight mechanisms.

At the federal level, the ongoing DEA rescheduling process remains the most significant policy development. If marijuana moves to Schedule III, it would acknowledge accepted medical use and reduce criminal penalties, though it would not legalize cannabis or resolve the fundamental conflict with state programs. The DEA's administrative law judge hearings on the proposed rule are scheduled to begin in September 2026, with a final rule expected in early 2027. A high-profile enforcement action in Virginia could influence the political environment surrounding rescheduling, either by highlighting ongoing federal concerns or by demonstrating that enforcement can target bad actors without disrupting compliant state markets.

Industry observers will monitor whether other U.S. Attorneys' offices initiate similar investigations in other state-legal markets. Federal enforcement often follows patterns—the 2020 California actions against alleged diversion operations preceded similar cases in Oklahoma and Oregon. If the Virginia investigation represents a new enforcement priority focused on state-program integrity, other jurisdictions with recent licensing controversies may face scrutiny.

For Virginia's cannabis operators, the near-term focus will be on ensuring strict compliance with all state regulations and maintaining detailed documentation of business practices. Operators should review their internal controls, inventory tracking procedures, and financial record-keeping to ensure they can demonstrate full compliance if subject to regulatory or law enforcement inquiries. Legal counsel advises operators to conduct privileged internal audits and address any identified deficiencies proactively.

Further Reading

• Virginia Cannabis Control Authority official website and regulations: https://www.cca.virginia.gov/
• Virginia Code § 4.1-1500 et seq., Cannabis Control Act: https://law.lis.virginia.gov/vacodefull/title4.1/chapter15/
• 21 U.S.C. § 801 et seq., Controlled Substances Act: https://www.govinfo.gov/content/pkg/USCODE-2021-title21/html/USCODE-2021-title21-chap13.htm
• HHS recommendation to reschedule marijuana to Schedule III (August 2023): https://www.hhs.gov/about/news/2023/08/30/hhs-recommends-rescheduling-marijuana.html
• DEA Notice of Proposed Rulemaking on marijuana rescheduling (May 2024): https://www.federalregister.gov/documents/2024/05/21/
• FinCEN guidance on marijuana-related businesses (February 2014): https://www.fincen.gov/resources/statutes-regulations/guidance/bsa-expectations-regarding-marijuana-related-businesses
• Gonzales v. Raich, 545 U.S. 1 (2005): https://supreme.justia.com/cases/federal/us/545/1/
• United States v. McIntosh, 833 F.3d 1163 (9th Cir. 2016): https://caselaw.findlaw.com/us-9th-circuit/1742781.html
• Marijuana Policy Project Virginia campaign resources: https://www.mpp.org/states/virginia/
• RAND Drug Policy Research Center cannabis publications: https://www.rand.org/topics/cannabis.html